Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Explores AI Content Marketplace With Media Publishers 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
PHILADELPHIA, Nov. 15, 2017 -- Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Philadelphia, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, was interviewed on CEOLIVE.TV on November 13, 2017.
The interview can be viewed at:
http://ceolive.tv/hemispherx-heb-ramping-up-manufacturing-to-pursue-multi-billion-dollar-immuno-oncology-market/
About CEOLIVE.TV
CEOLIVE.TV is an online investor media and news resource featuring interviews and commentary with top executives from U.S. publicly traded companies.
About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Contact
Phone Number: 800-778-4042
Email: [email protected]
